Instil Bio, Inc. (TIL)
7.58
-0.08
(-1.04%)
USD |
NASDAQ |
Sep 04, 16:00
7.58
0.00 (0.00%)
After-Hours: 20:00
Instil Bio Enterprise Value : 68.90M for Sept. 4, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 04, 2026 | 68.90M |
| September 03, 2026 | 69.44M |
| September 02, 2026 | 69.61M |
| September 01, 2026 | 69.64M |
| August 31, 2026 | 69.10M |
| August 28, 2026 | 68.90M |
| August 27, 2026 | 70.79M |
| August 26, 2026 | 70.59M |
| August 25, 2026 | 69.03M |
| August 24, 2026 | 70.46M |
| August 21, 2026 | 68.90M |
| August 20, 2026 | 67.88M |
| August 19, 2026 | 67.61M |
| August 18, 2026 | 67.06M |
| August 17, 2026 | 67.40M |
| August 14, 2026 | 67.54M |
| August 13, 2026 | 66.79M |
| August 12, 2026 | 68.22M |
| August 11, 2026 | 68.29M |
| August 10, 2026 | 67.74M |
| August 07, 2026 | 67.74M |
| August 06, 2026 | 66.86M |
| August 05, 2026 | 66.73M |
| August 04, 2026 | 66.66M |
| August 03, 2026 | 66.45M |
| Date | Value |
|---|---|
| July 31, 2026 | 65.78M |
| July 30, 2026 | 65.91M |
| July 29, 2026 | 66.45M |
| July 28, 2026 | 66.93M |
| July 27, 2026 | 65.98M |
| July 24, 2026 | 65.84M |
| July 23, 2026 | 66.32M |
| July 22, 2026 | 66.66M |
| July 21, 2026 | 66.66M |
| July 20, 2026 | 66.66M |
| July 17, 2026 | 67.81M |
| July 16, 2026 | 68.42M |
| July 15, 2026 | 69.17M |
| July 14, 2026 | 70.49M |
| July 13, 2026 | 69.30M |
| July 10, 2026 | 69.71M |
| July 09, 2026 | 69.44M |
| July 08, 2026 | 70.25M |
| July 07, 2026 | 70.05M |
| July 06, 2026 | 69.84M |
| July 02, 2026 | 69.91M |
| July 01, 2026 | 69.64M |
| June 30, 2026 | 69.64M |
| June 29, 2026 | 61.56M |
| June 26, 2026 | 60.88M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.941B |
| Alnylam Pharmaceuticals, Inc. | 35.27B |
| Anika Therapeutics, Inc. | 265.34M |
| Savara, Inc. | 960.37M |
| Vericel Corp. | 1.989B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.299M |
| Total Expenses (Quarterly) | 4.299M |
| EPS Diluted (Quarterly) | -0.6339 |
| Earnings Yield | -59.00% |
| Normalized Earnings Yield | -59.61 |